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Background: Methamphetamine-abuse is a worldwide health problem for which no effective therapy is available.
Inhibition of methamphetamine-induced transporter-mediated dopamine (DA) release could be a useful approach
to treat methamphetamine-addiction. We assessed the potencies of bupropion, methylphenidate, and 3,4-
methylenedioxypyrovalerone (MDPV) to block DA uptake or to inhibit methamphetamine-induced DA release in
HEK-293 cells expressing the human DA transporter.
Findings: Bupropion, methylphenidate, and MDPV inhibited methamphetamine-induced DA release with relative
potencies corresponding to their potencies to block DA uptake (potency ranks: MDPV >methylphenidate > bupropion).
Conclusions: Bupropion and methylphenidate antagonize the effects of methamphetamine in vitro and may be
potential candidates for the treatment of stimulant addiction. However, drugs that very potently antagonize the effect of
methamphetamine are likely to also exhibit considerable abuse liability (MDPV >methylphenidate > bupropion).
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Background
Methamphetamine dependence is a major public health
problem. Currently, no medical treatments are approved
for stimulant dependence indicating the need to explore
potential candidates [1]. Methamphetamine releases
dopamine (DA) via the DA transporter (DAT) [2,3].
DA is thought to mediate the reinforcing effects of
psychostimulants, which lead to drug dependence [4,5].
Blocking the pronounced release of DA by methampheta-
mine may therefore be an interesting therapeutic option for* Correspondence: matthias.liechti@usb.ch
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reproduction in any medium, provided the orthe treatment of methamphetamine dependence [1]. Bu-
propion and methylphenidate are DA uptake inhibitors that
interact with the same pharmacological target as metham-
phetamine [6-11]. Bupropion is used as an antidepressant
and smoking cessation aid [7,9]. Methylphenidate is effect-
ively used in the treatment of attention-deficit/hyperactivity
disorder [12,13]. In addition, small clinical studies indicated
promising beneficial effects for both medications in
methamphetamine dependence [1]. Bupropion reduced the
acute subjective effects of methamphetamine in a labora-
tory study [14] and methamphetamine use in dependent
patients with moderate drug use [15-18]. Methylphenidate
reduced amphetamine use in dependent patients [19] and it
is now being investigated in methamphetamine-addiction
(clinicaltrials.gov: NCT01044238). Bupropion also reduced
methamphetamine self-administration in rats [20] or rhesusl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.

























Figure 1 DA uptake inhibition by methamphetamine, bupropion,
methylphenidate, and MDPV. IC50 values are shown in Table 1. The
data are expressed as mean ± SEM of 3–4 independent experiments.
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affect methamphetamine self-administration in rhesus
monkeys [21].
The precise pharmacological mechanism of action of
bupropion and methylphenidate with regard to their
therapeutic effects in methamphetamine dependent pa-
tients is not known. Dopamine is thought to contribute to
the drug-high and euphoria produced by psychostimulants
and mediates the addictive properties of drugs of abuse
[4,22]. Amphetamines reverse the transport of DA through
the DAT and this effect is thought to play a key role in the
addictive potential of amphetamines [5]. The DA uptake
inhibitors bupropion and methylphenidate may therefore
prevent methamphetamine from interacting with the DAT
to release DA, and such an effect would antagonize effects
of methamphetamine. Several DA uptake inhibitors have
previously been shown to prevent DAT-mediated release of
DA by amphetamines in vitro. For example, bupropion and
methylphenidate [23] as well as GBR12909 [3] inhibited
DAT-mediated amphetamine- or methamphetamine
induced DA release from rat synaptosomes. In HEK-293
cells expressing human DAT, methylphenidate inhibited
DA efflux induced by methamphetamine [24]. These and
similar data suggest that bupropion and methylphenidate
block the interaction of methamphetamine with the
DAT to release DA and thereby act as antagonists of
amphetamine-like drugs.
The aim of the present study was to test and compare
the effects of bupropion and methylphenidate on
methamphetamine-induced DA efflux in HEK-293 cells
expressing human DAT in vitro. Bupropion and methyl-
phenidate were selected because of their availability as
licensed medications and the clinical data described above.
We also included 3,4-methylenedioxypyrovalerone (MDPV)
into the study because it has been shown to be a very
potent DAT inhibitor [10,25].
We hypothesized that 1) the DA uptake blockers would
prevent methamphetamine-induced DA release and 2)
the potencies of the drugs to inhibit methamphetamine-
induced DA release would correspond to their potencies
to block DA uptake.
Methods
Drugs
(±)-Bupropion hydrochloride was from Toronto Research
Chemicals (North York, Canada), d-methamphetamine,
(±)-methylphenidate, and (±)-MDPV were supplied as
hydrochloride salts by Lipomed (Arlesheim, Switzerland).
Inhibition of DA uptake
The potencies of the drugs to inhibit the DAT were
evaluated as previously described [26] in HEK-293 cells
(Invitrogen, Zug, Switzerland) stably transfected with
the human DAT [8].Inhibition of methamphetamine-induced DA release
We performed DA transporter mediated release experi-
ments as previously published [25] with slight modification.
In brief, HEK-293 cells expressing the human DAT as
stated above were cultured in 48 well-plates. Cells were
filled with 3H-DA, washed, and incubated with 250 μL
buffer containing the drug alone or in combinations. Drug
combinations were 10 μM of methamphetamine with
bupropion, methamphetamine, or MDPV in different
concentrations. DA release was stopped after 15 min by
removing the release buffer from the cells. To quantify
the DA release we determined the radioactivity in the
cells after another wash step. The residual radioactivity
in the cells after methamphetamine alone defined 100%
DA release. Baseline (0% release) was defined as the
radioactivity remaining in the cells treated with bupro-
pion, methylphenidate, or MDPV alone at the highest
concentration used.
Results
Inhibition of DA uptake
Bupropion, methylphenidate, and MDPV inhibited
the uptake of DA. MDPV was the most potent DAT
inhibitor followed by methylphenidate and bupropion.
Methamphetamine blocked DA uptake with similar
potency to bupropion (Figure 1).
Inhibition of methamphetamine-induced DA release
Methamphetamine released DA with a potency (EC50) of
1.56 μM (0.9 μM-2.8 μM, 95% CI) as shown previously
[25]. DA release induced with 10 μM methamphetamine
was inhibited concentration-dependently by bupropion,
methylphenidate, and MDPV (Figure 2). MDPV was
the most potent inhibitor of the methamphetamine-
induced DA release followed by methylphenidate and
bupropion (Figure 2). The IC50 values are shown in
Table 1. The potencies (IC50 values) of the drugs to
block DA release correlated highly with the potencies to
block DA uptake (Figure 3) as confirmed by a correlation
coefficient of >0.99, p < 0.05.

























Figure 2 Methamphetamine-induced DA release is inhibited by
bupropion, methylphenidate and MDPV. The corresponding IC50
values are shown in Table 1. DA release was induced with 10 μM
methamphetamine (100% release) and blocked with different
concentration of the inhibitors bupropion, methylphenidate or MDPV.
Baseline (0% release) was defined as the radioactivity remaining in the
cells treated with bupropion, methylphenidate, or MDPV alone. The
data are expressed as mean ± SEM of 3–4 independent experiments.
Figure 3 The potencies of the drugs (log IC50 values) to
inhibit DA uptake correlate linearly with their potencies
to inhibit methamphetamine-induced DA release
(correlation coefficient > 0.99, p < 0.05, regression line and 95%
confidence intervals).
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In the present study, the DA uptake inhibitor bupropion
inhibited DA release induced by methamphetamine.
This mechanism might underlie the reduction in the
methamphetamine-induced subjective drug high by bu-
propion pretreatment documented in a clinical laboratory
study [14] and the reduced methamphetamine consump-
tion in drug users treated with bupropion [15-18].
Methylphenidate also blocked the methamphetamine-
induced DA release similar to bupropion and this effect
may also antagonize the rewarding effects of metham-
phetamine and its use in dependent patients. In fact,
methylphenidate showed beneficial effects in amphet-
amine dependent patients [19] and is being investi-
gated for the treatment of methamphetamine addiction
(clinicaltrials.gov: NCT01044238). Thus, inhibition of
DA release might be a pharmacological mechanism
how DA uptake inhibitors reduced the subjective stimulant
drug effects or drug consumption in the clinical studies
noted above. In addition, methylphenidate and bupropion
also increase DA levels and therefore both drugs may also
act as substitution treatments for methamphetamine use.
In the present study we also included the very potent DA




IC50 (μM) (95% CI) IC50 (μM) (95% CI)
Methamphetamine 1.05 (0.7-1.5) -
Bupropion 1.76 (1.1-2.8) 14.2 (9.7-21)
Methylphenidate 0.14 (0.1-0.2) 1.67 (0.7-4.0)
MDPV 0.031(0.03-0.04) 0.28 (0.1-0.6)
Values are means of 3–4 independent experiments and 95% confidence
intervals (CI).drug as DA uptake inhibitor relates to its potency to
antagonize the pharmacological effect of methampheta-
mine. MDPV blocked methamphetamine-induced DA
release with high potency reflecting its high potency as an
uptake inhibitor. We found that the potencies of the drugs
to block methamphetamine-induced DA release correlated
closely and significantly with their potencies to act as DA
uptake inhibitors. The finding suggests that the more po-
tent a drug antagonizes the DA release produced by meth-
amphetamine the more potently it also blocks DA uptake.
This finding may have important clinical implications re-
garding the abuse liability of potential antagonist treatments
for methamphetamine dependence. With regard to the
drugs tested in the present study, the antidepressant bupro-
pion is a low-potency DA transporter inhibitor and it is
considered a drug that does not produce relevant euphoria
nor addiction [27,28]. Methylphenidate is an intermediate-
potency DA transporter inhibitor and is known to produce
euphoria at higher doses [29,30] and to have a relevant
abuse potential [31,32]. The cathinone MDPV is a high po-
tency DA transporter inhibitor and street designer drug
(“super coke”, “research chemical”, “bath salt”) with high
addiction potential similar to the DA releaser metham-
phetamine [25,33-35]. Our findings indicate that drugs that
potently and effectively antagonize the effect of metham-
phetamine are likely to exhibit high abuse liability them-
selves because they block DA uptake. In fact, the potency
of amphetamine-type stimulants to block DA uptake has
been shown to correlate with the doses used by humans
[25]. Furthermore, potent DA transport uptake inhibition is
sufficient to produce addiction because cocaine and MDPV
only block DA uptake and do not induce DA release as
methamphetamine [5,25]. It is therefore questionable
whether there are any compounds that do not activate the
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methamphetamine from interacting with DAT. On the
other hand, abuse liability of medications can be reduced
by using extended-release drug formulations.
Methamphetamine also has additional effects on the
DA system (e.g., on monoamine oxidase and the vesicular
monoamine transporter), which were not studied here.
These effects of methamphetamine take place within the
cells and are likely prevented by DAT inhibitors [36]
that block methamphetamine transport into the cell.
Methamphetamine also releases norepinephrine [2,3]
and norepinephrine is thought to contribute to the
acute effects of amphetamine-type drugs [3,37-39]. MDPV
[25] and methylphenidate [6,40], and to a lower extent
bupropion [7,11], block the norepinephrine transporter and
these drugs could also block methamphetamine-induced
norepinephrine release. We did not address potential drug
interactions at the norepinephrine transporter because in
contrast to DA, norepinephrine is not generally thought
to be a major mediator of the addictive properties of
psychostimulants. However, interactions at the norepin-
ephrine transporter could be expected to contribute to
any therapeutic effects of the drugs tested in the present
study. Finally, it should be noted that we assessed only a
small number of DAT inhibitors. However, the drugs were
selected to cover a wide range of DAT inhibition potencies
including also the very potent DAT inhibitor MDPV.Conclusion
Our in vitro studies and the limited clinical data indi-
cate that the low- and intermediate-potency DA uptake
inhibitors bupropion and methylphenidate may be potential
candidates as treatments of amphetamine-type stimu-
lant dependence [1] due to their property to inhibit
methamphetamine-induced DA efflux. Their clinical
efficacy needs further confirmation.Availability of supporting data
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